Indaptus Therapeutics, Inc.
INDP
$1.73
-$0.03-1.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 213.93% | -32.53% | -4.40% | -25.10% | -21.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.51% | -15.71% | 8.47% | 15.96% | -0.19% |
| Operating Income | -95.51% | 15.71% | -8.47% | -15.96% | 0.19% |
| Income Before Tax | -96.38% | 3.06% | -30.22% | -19.06% | -3.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.38% | 3.06% | -30.22% | -19.06% | -3.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.38% | 3.06% | -30.22% | -19.06% | -3.20% |
| EBIT | -95.51% | 15.71% | -8.47% | -15.96% | 0.19% |
| EBITDA | -95.50% | 15.72% | -8.46% | -15.98% | 0.18% |
| EPS Basic | 57.36% | 66.98% | 30.88% | 28.72% | 20.64% |
| Normalized Basic EPS | 57.36% | 66.98% | 30.88% | 28.72% | 20.64% |
| EPS Diluted | 57.36% | 66.98% | 30.88% | 28.72% | 20.64% |
| Normalized Diluted EPS | 57.36% | 66.98% | 30.88% | 28.72% | 20.64% |
| Average Basic Shares Outstanding | 360.53% | 193.49% | 88.43% | 67.06% | 30.07% |
| Average Diluted Shares Outstanding | 360.53% | 193.49% | 88.43% | 67.06% | 30.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |